Sarepta Therapeutics, Inc.
SRPTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Sarepta Therapeutics, Inc. (SRPT) is listed under Biotechnology. At a $1.87B market cap, Sarepta Therapeutics, Inc. ranks as a small-cap company within healthcare. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Market Cap
$1.87B
Beta
0.38
P/E (TTM)
—
P/E (Fwd)
7.24
EPS (TTM)
$-1.57
EPS (Fwd)
$2.45
ROE
-9.5%
ROA
-1.1%
Cash
$788.5M
Total Debt
$1.06B
Free CF
$22.1M
52W Change
-22.3%
Annual Financials
Cash vs Debt
Where SRPT stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, SRPT finished 11.71% below its 150-day moving average ($18.70) and 13.01% below its 200-day moving average ($18.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SRPT overbought or oversold?
At the October 14, 2026 close, SRPT's RSI(14) was 25.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $788.5M in cash, though total debt stands at $1.06B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $22.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -9.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $933.0M (2022) to $2.20B (2025), reflecting a 136% increase over the period.
The relatively low beta of 0.38 suggests SRPT is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SRPT.